Sterically hindered amine light stabilizers with a mixed functionalization
    3.
    发明授权
    Sterically hindered amine light stabilizers with a mixed functionalization 有权
    具有混合官能化的空间位阻胺光稳定剂

    公开(公告)号:US09550941B2

    公开(公告)日:2017-01-24

    申请号:US13879114

    申请日:2011-10-17

    摘要: A compound of the formula (I), wherein one or two radicals of the radicals R1 are independently of one another C1-C20alkyloxy or C3-C12cycloalkyloxy and the remaining radicals R1 are independently of one another hydrogen, C1-C20alkyl or C3-C12cycloalkyl; the radicals R0 and R2 are independently of one another hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a) with R3 being hydrogen, C1-C20alkyl, C3-C12cycloalkyl, C1-C20alkyloxy or C3-C12cycloalkyloxy; Y is C2-C12alkylene; m is 0 or 1; n is 1, 2 or 3; when n is 1, X is hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a); when n is 2, X is C2-C12alkylene; when n is 3, X is a group N(Z—)3 with Z being C2-C12alkyl.

    摘要翻译: 式(I)的化合物,其中基团R 1的一个或两个基团彼此独立地为C 1 -C 20烷氧基或C 3 -C 12环烷氧基,其余基团R 1彼此独立地为氢,C 1 -C 20烷基或C 3 -C 12环烷基; 基团R 0和R 2彼此独立地为氢,C 1 -C 20烷基,C 3 -C 12环烷基或式(II-a)基团,其中R 3为氢,C 1 -C 20烷基,C 3 -C 12环烷基,C 1 -C 20烷氧基或C 3 -C 12环烷氧基 ; Y是C 2 -C 12亚烷基; m为0或1; n为1,2或3; 当n为1时,X为氢,C 1 -C 20烷基,C 3 -C 12环烷基或式(II-a)基团; 当n为2时,X为C 2 -C 12亚烷基; 当n为3时,X为N(Z-)3,Z为C 2 -C 12烷基

    STERICALLY HINDERED AMINE LIGHT STABILIZERS WITH A MIXED FUNCTIONALIZATION
    6.
    发明申请
    STERICALLY HINDERED AMINE LIGHT STABILIZERS WITH A MIXED FUNCTIONALIZATION 有权
    具有混合功能化的异味胺类光稳定剂

    公开(公告)号:US20130207043A1

    公开(公告)日:2013-08-15

    申请号:US13879114

    申请日:2011-10-17

    IPC分类号: C09K15/30 C07D401/14

    摘要: A compound of the formula (I), wherein one or two radicals of the radicals R1 are independently of one another C1-C20alkyloxy or C3-C12cycloalkyloxy and the remaining radicals R1 are independently of one another hydrogen, C1-C20alkyl or C3-C12cycloalkyl; the radicals R0 and R2 are independently of one another hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a) with R3 being hydrogen, C1-C20alkyl, C3-C12cycloalkyl, C1-C20alkyloxy or C3-C12cycloalkyloxy; Y is C2-C12alkylene; m is 0 or 1; n is 1, 2 or 3; when n is 1, X is hydrogen, C1-C20alkyl, C3-C12cycloalkyl or a group of the formula (II-a); when n is 2, X is C2-C12alkylene; when n is 3, X is a group N(Z—)3 with Z being C2-C12alkyl

    摘要翻译: 式(I)的化合物,其中基团R 1的一个或两个基团彼此独立地为C 1 -C 20烷氧基或C 3 -C 12环烷氧基,其余基团R 1彼此独立地为氢,C 1 -C 20烷基或C 3 -C 12环烷基; 基团R 0和R 2彼此独立地为氢,C 1 -C 20烷基,C 3 -C 12环烷基或式(II-a)基团,其中R 3为氢,C 1 -C 20烷基,C 3 -C 12环烷基,C 1 -C 20烷氧基或C 3 -C 12环烷氧基 ; Y是C 2 -C 12亚烷基; m为0或1; n为1,2或3; 当n为1时,X为氢,C 1 -C 20烷基,C 3 -C 12环烷基或式(II-a)基团; 当n为2时,X为C 2 -C 12亚烷基; 当n为3时,X为N(Z-)3,Z为C 2 -C 12烷基

    Enzymatic Conversion of Epoxides to Diols
    8.
    发明申请
    Enzymatic Conversion of Epoxides to Diols 审中-公开
    环氧化物向二醇的酶转化

    公开(公告)号:US20090061494A1

    公开(公告)日:2009-03-05

    申请号:US11887982

    申请日:2006-04-03

    申请人: Kai-Uwe Schoning

    发明人: Kai-Uwe Schoning

    IPC分类号: C12P7/18 C12P7/62

    CPC分类号: C12P7/18 C12P7/62

    摘要: Diols of the formula I: or corresponding polymers wherein R1 has been integrated into a polymeric backbone, wherein n ranges from (1) to (4); X is a divalent linking group selected from the group consisting of ether, ester, amino and amido groups; R1 is an n-valent hydrocarbon residue containing at least one reactive group selected from the group consisting of carbon-carbon double or triple bonds and silyl groups; R2, R3 and R4 independently are hydrogen or C1-C4alkyl; are conveniently prepared by treatment of an epoxide of the formula II wherein all residues and the index n are as defined for formula I, or a corresponding polymer, with an epoxide hydrolase, e.g. from lyophilized cells of Aspergillus niger.

    摘要翻译: 式I的二醇或其中R 1已经整合到聚合物主链中的相应聚合物,其中n为(1)至(4); X是选自醚,酯,氨基和酰胺基的二价连接基团; R1是含有至少一个选自碳 - 碳双键或三键和甲硅烷基的反应性基团的n价烃基; R2,R3和R4独立地是氢或C1-C4烷基; 方便地通过处理式II的环氧化物制备,其中所有残基和指数n如式I所定义,或相应的聚合物与环氧化物水解酶如 来自黑曲霉的冻干细胞。

    Crystalline forms of atorvastatin
    9.
    发明申请
    Crystalline forms of atorvastatin 审中-公开
    阿托伐他汀的结晶形式

    公开(公告)号:US20060205805A1

    公开(公告)日:2006-09-14

    申请号:US11431184

    申请日:2006-05-09

    IPC分类号: A61K31/401 C07D207/337

    CPC分类号: C07D207/34

    摘要: The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. The present invention also is directed to crystalline Form A of Atorvastatin calcium (2:1) that is stable against the formation of the AED impurity. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.

    摘要翻译: 本发明涉及阿托伐他汀钙(2:1)的新结晶形式,以下称为多晶型X,A,B1,B2,C,D和E.本发明还涉及阿托伐他汀的晶型A 对于形成AED杂质是稳定的钙(2:1)。 此外,本发明涉及制备这些结晶形式的方法和包含结晶形式的药物组合物。